The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. The detection of mutated circulating tumor DNA by BEAMing technology addresses this gap in care and allows these patients to receive international guideline-recommended expanded RAS testing with rapid turnaround times. Furthermore, the overall concordance between OncoBEAM RAS colorectal cancer testing and standard of care tissue testing is very high (93.3%). This article presents an overview of the clinical utility and potential applications of this minimally invasive method, such as early detection of emergent resistance to anti-epidermal growth factor receptor therapy. If appropriately implemented, BEAMing technology holds considerable promise to enhance the quality of patient care and improve clinical outcomes.

中文翻译：

---

将BEAMing技术作为液体活检技术纳入大肠癌患者管理的临床实践：专家组审查。

用抗表皮生长因子受体试剂对晚期大肠癌进行突变鉴定的重要性已得到公认。但是，由于周转时间的延迟，质量低下的组织样本和/或缺乏测试方法的标准化，正在治疗大量患者，而没有Kirsten大鼠肉瘤和Neuroblastoma大鼠肉瘤（RAS）检测所能提供的信息。通过BEAMing技术检测突变的循环肿瘤DNA可解决这一护理方面的空白，并使这些患者能够以快速的周转时间接受国际指南推荐的扩展RAS检测。此外，OncoBEAM RAS大肠癌检测与护理组织检测标准之间的总体一致性非常高（93.3％）。本文概述了这种微创方法的临床应用和潜在应用，例如对抗表皮生长因子受体疗法的新出现耐药性的早期检测。如果实施得当，BEAMing技术可望提高患者护理质量并改善临床结果。